Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors
We are thrilled to welcome Heather to the Avalyn team and to her new role as Board Chair,” said Lyn Baranowski, chief executive officer of Avalyn. “As we look ahead, we are excited to tap into Heather ...
InnovationRx: Positive Clinical Trial Results For Generative AI-Designed Drug
Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.
marketinference15h
Gyre Therapeutics CEO expects pivotal phase 3 trial results in 2025
Financially, Gyre had cash and cash equivalents totaling $15.9 million as of September 30, 2024. For the third quarter of ...
The American Journal of Managed Care18h
Liver Fibrosis Scores May Hint at Heart Failure Risk
Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...
Pulmonary Fibrosis Foundation Launches Education Program For Newly Diagnosed Patients
The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...
Gyre Therapeutics, Inc.: Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...